Shares of Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) have been given an average rating of “Moderate Buy” by the four research firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $21.00.
Several equities research analysts have recently weighed in on CLBT shares. Lake Street Capital reduced their price target on Cellebrite DI from $24.00 to $22.00 and set a “buy” rating on the stock in a report on Friday, August 15th. Needham & Company LLC cut their price objective on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, August 14th. Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday. JPMorgan Chase & Co. boosted their target price on shares of Cellebrite DI from $20.00 to $23.00 and gave the company an “overweight” rating in a research note on Wednesday, September 24th. Finally, Wall Street Zen cut shares of Cellebrite DI from a “buy” rating to a “hold” rating in a report on Saturday.
View Our Latest Report on Cellebrite DI
Institutional Trading of Cellebrite DI
Cellebrite DI Stock Performance
NASDAQ:CLBT opened at $15.40 on Monday. The firm has a market capitalization of $3.69 billion, a PE ratio of -20.26, a PEG ratio of 3.16 and a beta of 1.28. The stock’s fifty day moving average is $17.76 and its 200 day moving average is $16.75. Cellebrite DI has a fifty-two week low of $13.10 and a fifty-two week high of $26.30.
Cellebrite DI (NASDAQ:CLBT – Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.01. The business had revenue of $113.28 million for the quarter, compared to analysts’ expectations of $112.33 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The business’s revenue was up 18.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.10 earnings per share. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities analysts forecast that Cellebrite DI will post 0.3 EPS for the current year.
Cellebrite DI Company Profile
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Stories
- Five stocks we like better than Cellebrite DI
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- 3 Big Earnings Misses: Is It Time to Buy the Dip?
- What is the Nikkei 225 index?
- Is Robinhood’s 11% Post-Earnings Fall a Buy-the-Dip Opportunity?
- How to Use the MarketBeat Stock Screener
- AI Demand Is Coming—Is Microchip Technology Ready?
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.
